Recent Comments

Comment RSS

Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

20. November 2009 09:23
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC). [More]

Posted in: Men's Health News | Pharmaceutical News

Tags: , , , , , ,

Permalink | Comments (0)

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

20. November 2009 04:41
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development. [More]

Posted in: Drug Trial News

Tags: , , ,

Permalink | Comments (0)

Comprehensive report on world cancer therapies market

20. November 2009 01:37
Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

Posted in: Device / Technology News

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

18. November 2009 11:24
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system. [More]

Posted in: Medical Research News | Medical Condition News

Tags: , , , , , , ,

Permalink | Comments (0)

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

18. November 2009 11:14
CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins). [More]

Posted in: Medical Science News | Disease/Infection News

Tags: , , , , , , , , ,

Permalink | Comments (0)

Assessing the neurology market and its major players

17. November 2009 04:13
Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Bend Memorial Clinic set to begin Phase III lung cancer trial

11. November 2009 23:12
The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC). [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , ,

Permalink | Comments (0)

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

11. November 2009 01:19
A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

New technique to identify patients more likely to survive advanced melanoma

10. November 2009 00:26
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Now it may be possible to identify which patients are more likely to survive by analyzing the activity of hundreds of genes involved in the immune response and gene proliferation, according to researchers at NYU Langone Medical Center. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Cellular mechanisms that may impact immune functions in the elderly discovered

9. November 2009 03:15
Investigators discover cellular mechanisms that may impact the decline of both innate and adaptive immune functions that increase the susceptibility to various infectious agents, cancer and diseases in the elderly say experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , ,

Permalink | Comments (0)

NewLink Genetics announces closing of its $30M Series C financing

6. November 2009 01:12
NewLink Genetics Corporation announced today that it has closed a $30 million Series C financing to accelerate the clinical development of its therapeutic cancer products. Total cash raised in 2009 under a combination of the previously announced Series D Preferred and the remaining shares in the Series C Preferred totaled just under $20 million. [More]

Posted in: Business / Finance

Tags: , , ,

Permalink | Comments (0)

Dietary options and better detection improve food allergy management procedures

5. November 2009 07:59
Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla. [More]

Posted in: Miscellaneous News

Tags: , , , , , , , , , , , , , ,

Permalink | Comments (0)

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

4. November 2009 08:21
Antigenics, Inc. today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world’s most clinically advanced malaria vaccine, is ongoing in seven African countries. [More]

Posted in: Child Health News | Pharmaceutical News

Tags: , , , ,

Permalink | Comments (0)

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

4. November 2009 07:47
Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

3. November 2009 07:11
High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent), according to the first randomized study of its kind presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.